BioNTech und Fosun Pharma arbeiten gemeinsam an der Entwicklung eines mRNA-basierten COVID-19-Impfstoffes in China
March 16, 2020 02:00 ET
|
BioNTech SE
BioNTech und Fosun Pharma werden gemeinsam klinische Studien für den Produktkandidaten BNT162 in China durchführen. Grundlage dafür bildet BioNTechs firmeneigene mRNA-Technologie sowie Fosuns...
BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China
March 16, 2020 02:00 ET
|
BioNTech SE
BioNTech and Fosun Pharma will jointly conduct clinical trials of BNT162 in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and...
BioNTech berichtet über rapide Fortschritte bei COVID-19-Impfstoff-Programm zur Bekämpfung der globalen Gesundheitsbedrohung
March 16, 2020 02:00 ET
|
BioNTech SE
BNT162-Impfstoffprogramm zur Prävention von COVID-19-Infektionen angekündigtBeginn der klinischen Studie im April 2020 erwartetPläne für ein globales Konsortium an Kollaborationspartnern im Kampf...
BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat
March 16, 2020 02:00 ET
|
BioNTech SE
Announces BNT162 vaccine program for the prevention of COVID-19 infectionAnticipates start of clinical testing for vaccine in late April 2020 Plans to assemble a global consortium of partners to...
CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide
March 15, 2020 12:06 ET
|
CureVac AG
The company rejects current rumors of an acquisition TÜBINGEN, Germany and BOSTON, March 15, 2020 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering...
Translate Bio Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Progress
March 12, 2020 16:45 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG
March 11, 2020 15:08 ET
|
CureVac AG
TÜBINGEN, Germany and BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that company...
CureVac-CEO Daniel Menichella berät mit US-Präsident Donald Trump und Mitgliedern der Corona Task Force Entwicklungsmöglichkeiten eines Coronavirus-Impfstoffes
March 03, 2020 01:30 ET
|
CureVac AG
Weißes Haus hat Vertreter von Pharmaunternehmen zur Bekämpfung von Covid-19 eingeladenCureVac wählt derzeit aus Vielzahl von Impfstoffkandidaten die besten für klinische Tests ausGMP-zertifizierte...
CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force
March 02, 2020 18:54 ET
|
CureVac AG
White House today invited representatives of pharmaceutical and biotech companies leading the COVID-19 response effortCureVac currently selecting best vaccine candidates for clinical trials from a...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
February 26, 2020 07:30 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...